1237.16 Tiotropium + Olodaterol (PHYSACTO[TM]) in COPD

• Research type

  Research Study

• Full title

  An exploratory, 12 week, randomised, partially double-blinded, placebo-controlled, parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed dose combination or tiotropium (both delivered by the Respimat® inhaler), supervised exercise training and behaviour modification on exercise capacity and physical activity in patients with Chronic Obstructive Pulmonary Disease (COPD) [PHYSACTO(TM)]

• IRAS ID

  142353

• Contact name

  Andrew Wilson

• Contact email

  a.m.wilson@uea.ac.uk

• Eudract number

  2013-002671-18

• ISRCTN Number

  NA

• Clinicaltrials.gov Identifier

  NA

• Research summary

  This is an exploratory, randomised, partially-double blinded trial to evaluate the effect of inhaled medication (orally inhaled tiotropium + olodaterol fixed dose combination or tiotropium, both delivered by Respimat® inhaler) together with exercise and activity training on exercise capacity and daily activities in patients with chronic lung disease with obstruction of airways. The research study will aim to recruit 300 patients worldwide.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  14/EM/0101

• Date of REC Opinion

  2 Apr 2014

• REC opinion

  Further Information Favourable Opinion